MA53513B1 - Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil - Google Patents
Combinaison à dose fixe et à libération immédiate de mémantine et de donépézilInfo
- Publication number
- MA53513B1 MA53513B1 MA53513A MA53513A MA53513B1 MA 53513 B1 MA53513 B1 MA 53513B1 MA 53513 A MA53513 A MA 53513A MA 53513 A MA53513 A MA 53513A MA 53513 B1 MA53513 B1 MA 53513B1
- Authority
- MA
- Morocco
- Prior art keywords
- memantine
- donepezil
- immediate
- dose
- fixed
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003530 donepezil Drugs 0.000 title abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 title abstract 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004640 memantine Drugs 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT2019115557 | 2019-05-31 | ||
| PCT/IB2020/055137 WO2020240505A1 (en) | 2019-05-31 | 2020-05-29 | Immediate release fixed-dose combination of memantine and donepezil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53513A MA53513A (fr) | 2021-09-08 |
| MA53513B1 true MA53513B1 (fr) | 2023-10-31 |
Family
ID=88650785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53513A MA53513B1 (fr) | 2019-05-31 | 2020-05-29 | Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil |
Country Status (7)
| Country | Link |
|---|---|
| ES (1) | ES2960207T3 (sr) |
| HU (1) | HUE063622T2 (sr) |
| LT (1) | LT3843702T (sr) |
| MA (1) | MA53513B1 (sr) |
| PL (1) | PL3843702T4 (sr) |
| RS (1) | RS64694B1 (sr) |
| SM (1) | SMT202300336T1 (sr) |
-
2020
- 2020-05-29 ES ES20732664T patent/ES2960207T3/es active Active
- 2020-05-29 SM SM20230336T patent/SMT202300336T1/it unknown
- 2020-05-29 RS RS20230893A patent/RS64694B1/sr unknown
- 2020-05-29 MA MA53513A patent/MA53513B1/fr unknown
- 2020-05-29 PL PL20732664.6T patent/PL3843702T4/pl unknown
- 2020-05-29 LT LTEPPCT/IB2020/055137T patent/LT3843702T/lt unknown
- 2020-05-29 HU HUE20732664A patent/HUE063622T2/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE063622T2 (hu) | 2024-01-28 |
| SMT202300336T1 (it) | 2023-11-13 |
| PL3843702T3 (pl) | 2024-04-08 |
| RS64694B1 (sr) | 2023-11-30 |
| LT3843702T (lt) | 2023-11-10 |
| ES2960207T3 (es) | 2024-03-01 |
| PL3843702T4 (pl) | 2024-04-08 |
| MA53513A (fr) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goldberg et al. | Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation–a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study | |
| MA54227B1 (fr) | Méthodes de traitement de la fibrose kystique | |
| MA39094B1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MA35513B1 (fr) | Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine | |
| MA52861B1 (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple | |
| MA62992B1 (fr) | Formulations de capsules | |
| MA69295B1 (fr) | Dose de départ de conjugués de pth | |
| EP3804736A4 (en) | PHARMACEUTICAL COMPOSITION WITH MESENCHYMAL STEM CELLS AS AN EFFECTIVE INGREDIENT TO PREVENT OR TREAT AN INFLAMMATORY DISEASE | |
| MA63248B1 (fr) | Formulations d'un inhibiteur de la kallicréine plasmatique | |
| MA63861A1 (fr) | Composition pharmaceutique de virus non enveloppé | |
| MA56330B1 (fr) | Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone | |
| Sheehan et al. | Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| FR3079141B1 (fr) | Utilisations de derives de curcumine | |
| EP4129298A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FIBROSIS | |
| MA53513B1 (fr) | Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil | |
| EP3795170C0 (en) | PHARMACEUTICAL COMPOSITION CONTAINING CCN5 AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASES | |
| EP3845516A4 (en) | NOVEL HIF-1ALFA INHIBITOR, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING THESE AS AN ACTIVE SUBSTANCE | |
| EP4125983A4 (en) | An oral pharmaceutical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of inflammatory disease and the use thereof | |
| MA54276B1 (fr) | Montélukast destinée au traitement de l'arthrose de la main | |
| MA70850A1 (fr) | Composition pharmaceutique d'anticorps anti-cd20 et son utilisation | |
| MA58507A1 (fr) | Composition pharmaceutique aqueuse de levilimab | |
| MA49754B1 (fr) | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag | |
| EP3964215A4 (en) | PHARMACEUTICAL COMPOSITION WITH 6-DIAZO-5-OXO-L-NORLEUCINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES | |
| MA56341B1 (fr) | Combinaison d'ibuprofène et de tramadol pour soulager la douleur |